Advertisement

Topics

Latest "Rocket Pharmaceuticals" News Stories

10:03 EST 18th February 2019 | BioPortfolio

Here are the most relevant search results for "Rocket Pharmaceuticals" found in our extensive news archives from over 250 global news sources.

More Information about Rocket Pharmaceuticals on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Rocket Pharmaceuticals for you to read. Along with our medical data and news we also list Rocket Pharmaceuticals Clinical Trials, which are updated daily. BioPortfolio also has a large database of Rocket Pharmaceuticals Companies for you to search.

Showing "Rocket Pharmaceuticals" News Articles 1–25 of 10,000+

Extremely Relevant

Rocket Pharma nets $68.5mm via FOPO

Gene therapies developer Rocket Pharmaceuticals Inc. netted $68.5mm via a follow-on public offering of 5.5mm common shares at...


Rocket Pharmaceuticals Announces Clearance of IND for RP-A501 Gene Therapy

Rocket Pharmaceuticals (Nasdaq: RCKT) a leading U.S.-based multi-platform gene therapy company, today announces the clearance of the Company’s Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for RP-A501. As quoted in the press release: “This acceptance marks the first Rocket-sponsored IND cleared for our AAV platform and the third for our … Cont...

Rocket Pharmaceuticals Announces Clearance of IND for RP-L201 Gene Therapy

Rocket Pharmaceuticals (Nasdaq:RCKT) a leading U.S.-based multi-platform gene therapy company, announces the clearance of the Company’s Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for RP-L201. As quoted in the press release: “This acceptance marks the second Rocket-Sponsored IND cleared for our ex-vivo lenti platform this quarter. We are excited...


Rocket, Inotek reverse merge

Public Inotek Pharmaceuticals Corp. entered into a definitive agreement to merge with closely held Rocket Pharmaceuticals Inc...

RMAT, fast-track statuses given to Rocket's Fanconi anemia drug

Rocket Pharmaceuticals' RP-L102, a lentiviral vector-based gene therapy that is being developed to treat patients with Fancon -More- 

Rocket's IND for leukocyte adhesion deficiency-I drug OK'd by FDA

Rocket Pharmaceuticals' investigational new drug application for its RP-L201 gene therapy received approval from the FDA, all -More- 

Rocket Pharmaceuticals Receives FDA Drug Clearance

The company’s drug, PR-L201, is in development to treat Leukocyte Adhesion Deficiency-I, a rare pediatric disease. The post Rocket Pharmaceuticals Receives FDA Drug Clearance appeared first on Investing News Network.

Relevant

Rocket Pharma nets $59.5mm via FOPO

Rocket Pharmaceuticals Inc. (focused on developing gene therapies for rare pediatric diseases) netted $59.5mm through the fol...

Rocket Pharma provides update on Fanconi anemia study in Spain

Rocket Pharmaceuticals unveiled updated long-term results from a Phase I/II study being conducted in Spain to assess its gene -More- 

Rocket Pharmaceuticals Announces Participation at Upcoming Investor Conferences

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, today announced that members of Rocket’s executive team will participate in the following upcoming investor conferences: Citi’s 13th Annual Biotech Conference on September 6, 2018 in Boston, MA ...

Rocket gets exclusive rights to REGENXBIO's NAV AAV vectors

REGENXBIO Inc. licensed Rocket Pharmaceuticals Inc. exclusive global rights (with rights to sublicense) to use its adeno-asso...

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy and Fast Track Designations for RP-L102 Gene Therapy for Fanconi Anemia

NEW YORK–(BUSINESS WIRE)–Rocket Pharmaceuticals, Inc. (Nasdaq: RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, today announces that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations to RP-L102, the Company’s lentiviral vector (LVV)-based gene therapy for the treatment of F...

Rocket Pharmaceuticals to Host Conference Call to Reveal First AAV Gene Therapy Program

Conference Call Scheduled for Monday, November 26, 2018, at 8:30 a.m. ET Rocket Pharmaceuticals, Inc. (Nasdaq: RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, today announces that management will host a conference call on Monday, November 26th , 2018, at 8:30 a.m. ET to reveal their first adeno-associated viral ...

Rocket Pharmaceuticals Announces Participation at Upcoming Conferences

- Gaurav Shah, M.D., Chief Executive Officer, Invited as Panel Member at The Galien Forum USA 2018 - Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, today announced that members of Rocket’s executive team will participate in the following upcoming conferences: ...

Rocket Pharmaceuticals to Join NASDAQ Biotechnology Index

Rocket Pharmaceuticals, Inc. (Nasdaq: RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, today announces that the Company has been selected for addition to the NASDAQ Biotechnology Index® (NASDAQ: NBI). Rocket’s addition to the NBI will become effective prior to market open on Monday, December 24, 2018. The N...

Nasa-funded Rocket to View Sun With X-ray Vision

NewsThe FOXSI sounding rocket will scour the Sun with X-ray vision, looking for the mysterious mini-explosions that heat the corona to millions of degrees.

Bottle Rocket Wins Top Honors in Innovation at Tech Titans 2018 Gala

DALLAS, Aug. 31, 2018 /PRNewswire/ -- Last Friday evening at the Tech Titans 18th Annual Awards Gala, Bottle Rocket took home the award for Most Read more...

United Launch Alliance Successfully Launches Final Delta II Rocket with NASA's ICESat-2

VANDENBERG AIR FORCE BASE, Calif., Sept. 15, 2018 /PRNewswire/ -- A United Launch Alliance (ULA) Delta II rocket carrying NASA's Ice, Cloud and land Elevation Read more...

Civilization Ventures Achieves Major Win With NASDAQ Listing of Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”) is an emerging multi-platform gene therapy company focused on developing first-in-class gene therapy treatments for rare, devastating diseases

‘Optical rocket’ created with intense laser light

In a recent experiment at the University of Nebraska-Lincoln, plasma electrons in the paths of intense laser light pulses were almost instantly accelerated close to the speed of light. Physics professor Donald Umstadter, who led the research, said the

Follow-on fundings pull in $275M for Acadia, $55M for Rocket

A follow-on funding has brought in $275 million for Acadia Pharmaceuticals, which is marketing Parkinson's disease psychosis  -More- 

Tonix Pharmaceuticals shares rocket after FDA green-lights design of new late-stage study of Tonmya for PTSD

The clinical-stage biotech said it planned to start the RECOVERY trial for the treatment of PTSD in the first quarter of 2019

$RCKT Presents Updated Long-Term Phase 1/2 Clinical Data of RP-L102 in Fanconi Anemia Patients https://www.businesswire.com/news/home/20181018005195/en/Rocket-Pharmaceuticals-Presents-Updated-Long-Term-Phase-12 …

$RCKT Presents Updated Long-Term Phase 1/2 Clinical Data of RP-L102 in Fanconi Anemia Patients https://www.businesswire.com/news/home/20181018005195/en/Rocket-Pharmaceuticals-Presents-Updated-Long-Term-Phase-12 …

Evaporative Sample Preparation Protocol Improves Natural Product Extraction

Genevac has published a technical article that describes how its Rocket™ Evaporator has been used by the Technical University of Munich (Germany) as a sample preparation tool for extraction of active phytochemicals from the leaves of Gymnema sylvestre. A Genevac Rocket Evaporator was chosen to dry the samples because of its high-volume sample capacity, unique technology that eliminates cross...

Follow-on roundup: Acadia raises $275M, Rocket pockets $55M


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks